Cholera

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

480%

Small Molecule

120%

+ 21 programs with unclassified modality

On Market (1)

Approved therapies currently available

CIPROApproved

ciprofloxacin

Bayer

oral1997

396K Part D

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BayerLEVERKUSEN, Germany

1 program

CiprofloxacinPhase 3Small Molecule1 trial

Active Trials

NCT00142272Completed180Est. Jul 2002

Emergent BioSolutionsMB - Winnipeg

5 programs

PXVX0200Phase 3

PXVX0200 Lot APhase 3

PXVX0200 10E8Phase 21 trial

PXVX0200Phase 1

Active Trials

NCT02145377Completed150Est. Mar 2015

Nordic PharmaFrance - Paris

4 programs

PXVX0200Phase 3

PXVX0200 Lot APhase 3

PXVX0200Phase 1

Bharat BiotechIndia - Hyderabad

2 programs

Hillchol vaccinePhase 3Vaccine1 trial

Active Trials

NCT05732766Unknown1,800Est. Aug 2023

NCT05507229Unknown1,800Est. Oct 2022

EuBiologicsKorea - Seoul

2 programs

Oral Cholera Vaccine SimplifiedPhase 3Vaccine1 trial

Test Oral Cholera VaccinePhase 3Vaccine1 trial

Active Trials

NCT04760236Completed2,530Est. Mar 2023

NCT02502331Unknown442Est. Aug 2016

Allergy TherapeuticsUK - West Sussex

5 programs

VaxchoraPhase 21 trial

CHoBI7 mHealth program ArmN/A1 trial

Cholera-Hospital-Based-Intervention-for-7-DaysN/A1 trial

Immunity to Human Cholera in BangladeshN/A1 trial

Protective Immunity to Human Cholera in BangladeshN/A1 trial

Active Trials

NCT04816552Completed284Est. Nov 2021

NCT06003816Recruiting3,140Est. Nov 2026

NCT00401934Completed400Est. Dec 2012

+2 more trials

MSDIreland - Ballydine

1 program

HL-OCVPhase 1/21 trial

Active Trials

NCT02823899Completed840Est. Nov 2017

Bavarian NordicDenmark - Kvistgard

4 programs

PXVX0200PHASE_11 trial

PXVX0200PHASE_31 trial

PXVX0200 Lot APHASE_31 trial

Active Trials

NCT01585181Completed66Est. Jan 2013

NCT01895855Completed197Est. Nov 2014

NCT02100631Completed398Est. Jun 2015

+1 more trials

Alliance PharmaceuticalsUK - Wiltshire

1 program

ShancholN/A1 trial

Active Trials

NCT02727855Completed75,170Est. Oct 2019

PharmaronRI - Coventry

1 program

iOWH032PHASE_21 trial

Active Trials

NCT04150250Completed47Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Bharat BiotechHillchol vaccine

EuBiologicsOral Cholera Vaccine Simplified

EuBiologicsTest Oral Cholera Vaccine

Bavarian NordicPXVX0200

Bavarian NordicPXVX0200 Lot A

Bavarian NordicPXVX0200

BayerCiprofloxacin

PharmaroniOWH032

Allergy TherapeuticsVaxchora

Emergent BioSolutionsPXVX0200 10E8

MSDHL-OCV

Bavarian NordicPXVX0200

Allergy TherapeuticsCholera-Hospital-Based-Intervention-for-7-Days

Allergy TherapeuticsCHoBI7 mHealth program Arm

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 90,749 patients across 18 trials

NCT05732766 Bharat BiotechHillchol vaccine

To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)

Start: Feb 2023Est. completion: Aug 20231,800 patients

Phase 3Unknown

NCT05507229 Bharat BiotechHillchol vaccine

A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).

Start: Feb 2022Est. completion: Oct 20221,800 patients

Phase 3Unknown

NCT04760236 EuBiologicsOral Cholera Vaccine Simplified

Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Start: Oct 2021Est. completion: Mar 20232,530 patients

Phase 3Completed

NCT02502331 EuBiologicsTest Oral Cholera Vaccine

Safety and Immunogenicity of a New Formulation of Euvichol®

Start: Mar 2016Est. completion: Aug 2016442 patients

Phase 3Unknown

NCT02100631 Bavarian NordicPXVX0200

A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults

Start: May 2014Est. completion: Jun 2015398 patients

Phase 3Completed

NCT02094586 Bavarian NordicPXVX0200 Lot A

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

Start: May 2014Est. completion: Jun 20153,146 patients

Phase 3Completed

NCT01895855 Bavarian NordicPXVX0200

Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Start: Sep 2013Est. completion: Nov 2014197 patients

Phase 3Completed

NCT00142272 BayerCiprofloxacin

Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial

Start: May 2001Est. completion: Jul 2002180 patients

Phase 3Completed

NCT04150250 PharmaroniOWH032

Cholera Anti-Secretory Treatment Trial

Start: Nov 2019Est. completion: Jul 202047 patients

Phase 2Completed

NCT03251495 Allergy TherapeuticsVaxchora

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Start: Aug 2017Est. completion: Nov 202534 patients

Phase 2Completed

NCT02145377 Emergent BioSolutionsPXVX0200 10E8

PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Start: Jul 2014Est. completion: Mar 2015150 patients

Phase 2Completed

NCT02823899 MSDHL-OCV

Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

Start: Jul 2016Est. completion: Nov 2017840 patients

Phase 1/2Completed

NCT01585181 Bavarian NordicPXVX0200

Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200

Start: Apr 2012Est. completion: Jan 201366 patients

Phase 1Completed

NCT06003816 Allergy TherapeuticsCholera-Hospital-Based-Intervention-for-7-Days

Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)

Start: Oct 2023Est. completion: Nov 20263,140 patients

N/ARecruiting

NCT04816552 Allergy TherapeuticsCHoBI7 mHealth program Arm

Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change

Start: Mar 2021Est. completion: Nov 2021284 patients

N/ACompleted

NCT02727855 Alliance PharmaceuticalsShanchol

Cholera Vaccine Investment Strategy in Bangladesh

Start: Jan 2016Est. completion: Oct 201975,170 patients

N/ACompleted

NCT00349999 Allergy TherapeuticsProtective Immunity to Human Cholera in Bangladesh

Protective Immunity to Human Cholera in Bangladesh

Start: Jun 2008Est. completion: Dec 2012125 patients

N/ACompleted

NCT00401934 Allergy TherapeuticsImmunity to Human Cholera in Bangladesh

Immunity to Human Cholera in Bangladesh

Start: Dec 2006Est. completion: Dec 2012400 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

11 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 90,749 patients

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.